Subcutaneous patient-derived medulloblastoma xenograft model

All animal studies were performed in accordance with the Animal Care and Use Rules at the University of California San Diego (UCSD). The protocol (#{"type":"entrez-protein","attrs":{"text":"S11253","term_id":"83507","term_text":"pir||S11253"}}S11253) was approved by Institutional Animal Care and Use Committee (IACUC) of UCSD. NSG mice, 4–6 weeks old, were injected subcutaneously at shoulders and flanks with 1 × 10⁶ viable MB-PDX cells in 1:1 HBSS and gelatinous protein mixture Matrigel. After seven days, vehicle or Nilotinib (40 mg per Kg) treatment was started and given daily intraperitoneally. The tumor size was measured three times a week with a caliper, and tumor volumes were calculated according to the formula (length × width × width × 0.5). At day 42 post-grafting, all mice were euthanized by isoflurane inhalation and cervical dislocation. Tumors were harvested and stored for qRT-PCR analysis.